CA2378249A1 - Utilisation de fviia ou d'un antagoniste de facteur tissulaire tf pour reguler l'expression genique, et migration cellulaire ou chimiotaxie - Google Patents

Utilisation de fviia ou d'un antagoniste de facteur tissulaire tf pour reguler l'expression genique, et migration cellulaire ou chimiotaxie Download PDF

Info

Publication number
CA2378249A1
CA2378249A1 CA002378249A CA2378249A CA2378249A1 CA 2378249 A1 CA2378249 A1 CA 2378249A1 CA 002378249 A CA002378249 A CA 002378249A CA 2378249 A CA2378249 A CA 2378249A CA 2378249 A1 CA2378249 A1 CA 2378249A1
Authority
CA
Canada
Prior art keywords
fvlla
cell
phe
tissue factor
cells
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002378249A
Other languages
English (en)
Inventor
Mirella Ezban
Lars Christian Petersen
Agneta Siegbahn
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novo Nordisk Health Care AG
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2378249A1 publication Critical patent/CA2378249A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/36—Blood coagulation or fibrinolysis factors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6424—Serine endopeptidases (3.4.21)
    • C12N9/6437—Coagulation factor VIIa (3.4.21.21)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/21—Serine endopeptidases (3.4.21)
    • C12Y304/21021—Coagulation factor VIIa (3.4.21.21)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Zoology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Dermatology (AREA)
  • Urology & Nephrology (AREA)
  • Oncology (AREA)
  • Vascular Medicine (AREA)
  • Hematology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)

Abstract

L'invention concerne l'utilisation d'un agoniste TF et/ou FVII et/ou FVIIa, et/ou d'un antagoniste TF et/ou FVIIai, dans le traitement thérapeutique d'états pathologiques pouvant être associés à la migration cellulaire, ou traités par régulation spécifique de la migration cellulaire ou chimiotaxie. L'invention concerne également l'utilisation d'un agoniste TF et/ou FVII et/ou FVIIa, et/ou d'un antagoniste TF et/ou FVIIai dans le traitement d'états pathologiques pouvant être associés à la régulation de l'expression d'au moins un gène dans une cellule, par exemple le gène Cyr61.
CA002378249A 1999-07-14 2000-07-14 Utilisation de fviia ou d'un antagoniste de facteur tissulaire tf pour reguler l'expression genique, et migration cellulaire ou chimiotaxie Abandoned CA2378249A1 (fr)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
DKPA199901023 1999-07-14
DKPA199901023 1999-07-14
US14830099P 1999-08-11 1999-08-11
DKPA199901117 1999-08-12
DKPA199901117 1999-08-12
PCT/DK2000/000401 WO2001005353A2 (fr) 1999-07-14 2000-07-14 UTILISATION DE FVIIa OU D'UN ANTAGONISTE DE FACTEUR TISSULAIRE TF POUR REGULER L'EXPRESSION GENIQUE, ET MIGRATION CELLULAIRE OU CHIMIOTAXIE

Publications (1)

Publication Number Publication Date
CA2378249A1 true CA2378249A1 (fr) 2001-01-25

Family

ID=27221063

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002378249A Abandoned CA2378249A1 (fr) 1999-07-14 2000-07-14 Utilisation de fviia ou d'un antagoniste de facteur tissulaire tf pour reguler l'expression genique, et migration cellulaire ou chimiotaxie

Country Status (19)

Country Link
US (3) US20020193302A1 (fr)
EP (1) EP1200116B1 (fr)
JP (1) JP2003525028A (fr)
KR (1) KR100821644B1 (fr)
CN (1) CN100411684C (fr)
AT (1) ATE411041T1 (fr)
AU (1) AU5807500A (fr)
BR (1) BR0012408A (fr)
CA (1) CA2378249A1 (fr)
CZ (1) CZ200240A3 (fr)
DE (1) DE60040539D1 (fr)
ES (1) ES2316372T3 (fr)
HU (1) HUP0302052A3 (fr)
IL (1) IL147294A0 (fr)
MX (1) MXPA02000468A (fr)
NO (1) NO20020130L (fr)
PL (1) PL353035A1 (fr)
RU (1) RU2268744C2 (fr)
WO (1) WO2001005353A2 (fr)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001098359A2 (fr) * 2000-06-21 2001-12-27 Wyeth Cyr61 utilise comme cible dans le traitement et le diagnostic du cancer du sein
DE10238429A1 (de) 2002-03-19 2003-10-30 Aventis Behring Gmbh Intellect Marburg I Mutante der Faktor VII aktivierenden Protease (FSAP) als Risikofaktor für Atherosklerose
EP1443956A2 (fr) * 2001-11-02 2004-08-11 Novo Nordisk Health Care AG Utilisation d'un agoniste ou d'un antagoniste du facteur tissulaire pour le traitement d'etats associes a l'apoptose
US6858587B2 (en) 2001-11-02 2005-02-22 Novo Nordisk Pharmaceuticals, Inc. Use of tissue factor agonist or tissue factor antagonist for treatment of conditions related to apoptosis
AU2003214920A1 (en) * 2002-02-04 2003-09-02 Millennium Pharmaceuticals Inc. Methods and compositions for treating hematological disorders
EP1660658A2 (fr) * 2003-08-06 2006-05-31 Hans Peter B. Prydz Utilisation du silencage sirna dans la prevention des metastases
US20070207154A1 (en) * 2004-04-16 2007-09-06 Martin Friedlander Method of modulating vascularization
CA2628238A1 (fr) * 2005-11-07 2007-05-18 The Scripps Research Institute Compositions et procedes destines a controler la specificite de la signalisation du facteur tissulaire
WO2008103812A1 (fr) * 2007-02-21 2008-08-28 Yale University Compositions et procédés de diagnostic et de traitement de l'endométriose
ES2604110T3 (es) * 2011-07-01 2017-03-03 Shiseido Company, Ltd. Activador de la producción del factor de crecimiento derivado de plaquetas-BB, y activador de la producción de células madre mesenquimatosas, estabilizador de células madre y regenerador de la dermis comprendiendo cada uno el mismo
CN109381478A (zh) * 2018-10-31 2019-02-26 青岛大学附属医院 一种miRNA在制备抑制新生血管生成和抑制VEGF-A因子表达的试剂中的应用

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1993006855A1 (fr) 1991-10-11 1993-04-15 Novo Nordisk A/S Composition hemostatique pour hemostase locale
DE19538715A1 (de) * 1995-10-18 1997-04-30 Behringwerke Ag Verfahren zur Reinigung von Faktor VII und aktiviertem Faktor VII
US6413735B1 (en) * 1996-03-15 2002-07-02 Munin Corporation Method of screening for a modulator of angiogenesis
AU7907398A (en) 1997-06-23 1999-01-04 Novo Nordisk A/S Use of fviia for the treatment of bleedings in patients with a normal blood clotting cascade and normal platelet function
US20030040481A1 (en) * 1997-07-18 2003-02-27 Lars Kongsbak Methods for modifying cell motility using a factor VIIa antagonist
EP1005361B1 (fr) 1997-07-18 2010-01-06 Novo Nordisk Health Care AG Utilisation de fvii ou fviiai pour le traitement de perturbations fonctionelles endotheliaux respectivement pour l'inhibition de l'angiogenese
AT408613B (de) * 1998-06-17 2002-01-25 Immuno Ag Pharmazeutisches faktor vii-präparat
US7015194B2 (en) * 2000-05-10 2006-03-21 Novo Nordisk A/S Pharmaceutical composition comprising factor VIIa and anti-TFPI
HUP0401124A3 (en) 2001-03-22 2006-01-30 Novo Nordisk Healthcare Ag Coagulation factor vii derivatives
CN1522151A (zh) 2001-05-02 2004-08-18 ŵ��Ų�ڿ˹�˾ 经修饰的fvii用于治疗ards
WO2003007983A1 (fr) 2001-07-20 2003-01-30 Novo Nordisk Health Care Ag Composition pharmaceutique contenant des polypeptides du facteur vii et des polypeptides du facteur xi
EP1446149A1 (fr) 2001-11-09 2004-08-18 Novo Nordisk Health Care AG Composition pharmaceutique comprenant des polypeptides de facteur vii et des polypeptides de facteur v
EP1446147A1 (fr) 2001-11-09 2004-08-18 Novo Nordisk Health Care AG Composition pharmaceutique comprenant des polypeptides du facteur vii et de l'acide tranexamique
JP2006510568A (ja) 2001-11-09 2006-03-30 ノボ ノルディスク ヘルス ケア アクチェンゲゼルシャフト Ｖｉｉ因子ポリペプチドおよびイプシロン―アミノカプロン酸を含む薬学的組成物
EP1446155A1 (fr) 2001-11-09 2004-08-18 Novo Nordisk A/S Composition pharmaceutique comportant des polypeptides du facteur vii et des polypeptides d'aprotinine

Also Published As

Publication number Publication date
ATE411041T1 (de) 2008-10-15
CN1460024A (zh) 2003-12-03
PL353035A1 (en) 2003-10-06
NO20020130D0 (no) 2002-01-11
US20090036378A1 (en) 2009-02-05
US20050239708A1 (en) 2005-10-27
NO20020130L (no) 2002-03-13
EP1200116A2 (fr) 2002-05-02
AU5807500A (en) 2001-02-05
KR20020025194A (ko) 2002-04-03
CZ200240A3 (cs) 2003-04-16
IL147294A0 (en) 2002-08-14
EP1200116B1 (fr) 2008-10-15
US7829529B2 (en) 2010-11-09
DE60040539D1 (de) 2008-11-27
KR100821644B1 (ko) 2008-04-11
MXPA02000468A (es) 2008-10-06
HUP0302052A3 (en) 2005-12-28
CN100411684C (zh) 2008-08-20
RU2268744C2 (ru) 2006-01-27
US20020193302A1 (en) 2002-12-19
ES2316372T3 (es) 2009-04-16
WO2001005353A2 (fr) 2001-01-25
WO2001005353A3 (fr) 2001-07-19
HUP0302052A2 (hu) 2003-09-29
JP2003525028A (ja) 2003-08-26
BR0012408A (pt) 2002-03-12

Similar Documents

Publication Publication Date Title
US7829529B2 (en) Use of factor VIIa or a tissue factor antagonist for regulating gene expression and cell migration or chemotaxis
Tsopanoglou et al. Thrombin promotes angiogenesis by a mechanism independent of fibrin formation
Mirza et al. The proteinase activated receptor-2 (PAR-2) mediates mitogenic responses in human vascular endothelial cells.
AU676168B2 (en) Truncated tissue factor and FVIIa or FVII activator for blood coagulation
US6268163B1 (en) Identification of drug candidates modulating factor VII-mediated intracellular signaling
KR100882482B1 (ko) 사람 응고 인자 ｖｉｉ 변이체
JP4361728B2 (ja) ヒト凝固因子ｖｉｉ変異型
Nachman Thrombosis and atherogenesis: molecular connections
US6315995B1 (en) Methods for treating an ischemic disorder and improving stroke outcome
Black et al. Substrate specificity and inducibility of TACE (tumour necrosis factor α-converting enzyme) revisited: the Ala-Val preference, and induced intrinsic activity
Duffy et al. Plasminogen activator and cancer
US6461610B1 (en) Methods for modifying cell motility using factor VIIa or inactivated factor VIIa
JP3270462B2 (ja) ハイブリッドプロテインｃ
Arribas et al. Shedding of plasma membrane proteins
US20030125255A1 (en) Use of tissue factor agonist or tissue factor antagonist for treatment of conditions related to apoptosis
EP1952822A1 (fr) Polypeptides de facteur VII avec une affinité améliorée pour les plaquettes
Sanderson et al. Hydrogen peroxide and endothelin‐1 are novel activators of betacellulin ectodomain shedding
US20050245449A1 (en) Methods for modifying cell motility using factor VIIa antagonist
JP2013517782A (ja) 因子ｖｉｉ融合ポリペプチド
WO2008117179A2 (fr) Nouveaux polynucléotides et polypeptides du gène du facteur vii humain
WO2003037361A2 (fr) Utilisation d'un agoniste ou d'un antagoniste du facteur tissulaire pour le traitement d'etats associes a l'apoptose
Meyer Cellular effects of tissue factor binding proteins
UA75865C2 (en) USE OF AGONIST OF TISSUE FACTOR FVII OR FVIIa FOR TREATING PATHOLOGIES ASSOCIATED WITH CELL MIGRATION OR CHEMOTAXIS

Legal Events

Date Code Title Description
EEER Examination request
FZDE Discontinued